CEO & President
Dr Brian Salmons is the CEO & President and one of the founders of the company.
Prior to founding SG Austria, he was the Managing Director of Austrianova Singapore, founder of Austrianova Biotechnology GmbH, CEO of Austrian-Nordic Biotherapeutics and Scientific Director of Bavarian Nordic.
He was directly responsible for the Phase I/II clinical trial of an encapsulated cell product and was actively involved in Bavarian Nordic’s IPO in 1998.
Before joining Bavarian Nordic in 1994, he spent 10 in years in academia at research institutes in Switzerland, the U.S. and at the Ludwig-Maximilians-University Munich and is author or co-author of more than 100 scientific publications as well as the co-inventor on a number of important international patents and patent applications pertaining to SG Austria’s technology.
Professor Walter H. Günzburg, Ph.D.is the Chairman and one of the founders of the company.
He is also the Professor of Virology at the University of Veterinary Medicine, Vienna, Adjunct Professor at the National University of Singapore and the director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development in Vienna.
Prior to founding SG Austria, he was the Chairman of the board of Austrianova Biotechnology GmbH and Austrianova Biomanufacturing AG. He is also adviser to Paktis (Germany) and Tocagen (USA), as well as a founder and boardmember (and former Chairman) of Virusure GmbH.
In addition, he is a member of the editorial board of a number of international gene and cell therapy journals and a founding member of the Austrian Network for Gene Therapy.
Professor Günzburg has more than 20 years experience in virology, and over thirteen years experience in cell therapy and bioencapsulation, has published numerous peer reviewed scientific publications and book chapters in the field and is inventor of 17 patents and patent applications.
Chief Operating Officer
Dr John Dangerfield was appointed Chief Operating Officer of SG Austria in 2010, having previously been Head of Laboratory (2007-2010).
Previous to working with SG Austria he was a Group Leader at the Institute of Virology at the University of Veterinary Medicine in Vienna, Austria, where he still holds a position at and is involved in supervising research which he started before moving to Singapore in 2007.
Prior to this he worked in quality control for pharmaceuticals at Amersham Pharmacia Biotech in UK.
Chief Financial Officer
Louise Bussieres was appointed Chief Financial Officer of SG Austria in 2011. She is a certified Chartered Accountant with 30 years experience in accounting and finance. She is also a non-Executive Director of Innoheart Pte. Ltd., with other consulting interests as Principal of Bussieres Consulting Pte Ltd.
Prior to 2010, Ms. Bussieres was the Vice-President, Finance of LAB Research Inc. and Chief Financial Officer of LAB International Inc., two publicly traded Canadian pharmaceutical research organizations. From 1995 to 1999, she was Associate Director of the Experimental Biology Centre, the pre-clinical facility of the Institute of National Scientific Research of Quebec. Prior to 1995, Ms. Bussieres held several positions at KPMG, an international auditing and consulting firm.
Throughout her career, Ms. Bussieres has been involved in strategic planning, financing, accounting, mergers and acquisitions, treasury and contract negotiations in the pharmaceutical research and development field.
Dr Eva-Maria (Lilli) Brandtner was appointed Chief Scientist at SG Austria in 2010.
Previously, she held senior scientific posts at SG Austria and Austrianova Biomanufacturing AG and was Head of Quality Control at Bendermedsystems Diagnostics.
She is the co-author of 9 publications.
Dr. Stephen K. Rhind has over 25 years business development and funding related experience in the pharmaceutical and biomedical industry.